Overview
The Inflation Reduction Act (IRA) is set to bring significant changes to the pharmaceutical industry. With the final negotiated maximum fair price (MFP) for the first 10 selected products announced on September 1, 2024, and set to take effect on January 1, 2026, the landscape is already shifting.
Join us for an engaging cross-disciplinary program that will examine the IRA’s potential impact on pharmaceutical patent dynamics and drug valuation and pricing, as well as pending legal challenges to the IRA.
Discussion topics include the IRA’s impact on:
- Existing incentives to encourage investment in post-approval research and development
- Strategic investment decisions in pharmaceutical products
- The biosimilar and generic markets, including market entry strategies
- Drug pricing dynamics, including proposed methodologies for identifying and reconciling purchases for drugs subject to the MFP and eligible for 340B pricing
- The pending legal challenges to the IRA and their future impact on the program
CLE credit is pending. McDermott is an accredited CLE provider in California, Illinois, and New York. We can issue reciprocal credit for lawyers licensed in Connecticut, Florida, and New Jersey. For all other jurisdictions not listed, attendees will be provided with a Universal Certificate of Attendance, which they may use to self-apply for CLE credit in their state of admission. Attendees should contact their state’s CLE Board for current rules, regulations, and guidance.
